Industry proponents say continuous manufacturing produces better quality pharmaceutical products and at lower cost than those produced by batch processes. Sell the economic benefits to upper management, they say, and don’t be discouraged by the higher initial costs and perceived regulatory roadblocks.
Speakers at an American Association of Pharmaceutical Scientists (AAPS) meeting on continuous manufacturing of solid oral dose products attested to these cost, time and quality advantages of